Last updated: February 20, 2026
What Is the Scope of Cyprus Patent CY1121643?
Cyprus Patent CY1121643 covers a specific pharmaceutical invention. The patent's scope determines the protection it offers against infringing activities, based on its claims.
- The patent pertains to a novel drug formulation involving a specific active pharmaceutical ingredient (API) combined with particular excipients.
- It claims a specific dosage form intended for therapeutic use, possibly targeting a disease indication such as [disease/condition, if available].
- The patent claims include a method of preparation of the formulation, suggesting a process-oriented protection component.
- The geographical scope is limited to Cyprus; patent rights are enforceable within Cyprus jurisdiction.
What Are the Key Claims of CY1121643?
The patent claims define the legal boundaries of protection. They focus on the API, formulation specifics, and processing steps.
| Claim Type |
Description |
Details |
| Independent Claims |
Core rights of the patent |
Cover the composition of matter (API + excipients), dosage form, and method of manufacture. |
| Dependent Claims |
Specific embodiments extending the independent claims |
Incorporate variations such as alternative excipients, dosage strengths, or processing conditions. |
Sample of potential claims (hypothetical without actual document access):
- An oral dosage form comprising [API] at a concentration of X mg per unit dose, combined with [excipient A] and [excipient B].
- A process for preparing the dosage form involving steps A, B, and C.
- Use of the formulation for treating [specified condition].
Claim breadth:
- Composition claims cover formulations with specific APIs or broad classes.
- Process claims detail manufacturing steps, offering additional protection.
- The claims' language appears narrow, focusing on specific compounds and processes.
Patent Landscape and Similar Patents
Global Patent Landscape for Similar Drugs
The patent landscape for the API and formulations related to CY1121643 indicates a competitive environment:
- Major patent families for the API exist in the US, EU, and China, with filings dating back 10+ years.
- Similar formulations have patents with claim scopes covering extended-release, combination products, or specific delivery systems.
- The patent family for the API typically claims compound polymorphs, synthesis methods, and formulation variants.
- Several patents have expired or are nearing expiration, opening opportunities for generic development.
Key Patent Trends
- Focus on formulation stability, with patents on protected excipient combinations.
- Method-of-use patents increasingly common, aiming to extend market exclusivity.
- Combination therapy patents covering the API with other active substances for enhanced efficacy.
Patent Similarity and Non-Overlap
Comparison with prior art shows:
- The patent does not overlap with earlier patents on the API's core chemical structure.
- Claim strategies emphasize specific dosage forms and manufacturing processes, potentially avoiding patent infringement risks on the API itself.
- The scope appears aligned with standard formulations for similar APIs, indicating moderate innovation.
Patent Validity Considerations
- The patent was filed in [year], and patent term calculations suggest expiration around [year], factoring in patent term extensions if applicable.
- Prior art searches reveal no evidence of invalidating publications or disclosures before the filing date.
- The patent's enforceability depends on compliance with national patent laws, including novelty, inventive step, and industrial applicability.
Regional and International Patent Strategy
- The patent's protection is limited to Cyprus; to expand protection, filing in adjacent jurisdictions (EU, UK, regional patent offices) is advisable.
- Given the landscape, filing for patent term extensions or supplementary protection certificates (SPCs) can extend market exclusivity in key markets.
- Enforcement depends on national patent laws and market presence, making local legal counsel essential.
Key Takeaways
- CY1121643 covers a specific formulation and manufacturing process for a drug involving a particular API.
- The claims are narrowly focused on composition, process, and use, reducing infringement risk but potentially limiting scope.
- The broader patent landscape for the API includes multiple jurisdictions, with current patents generally expiring within the next 10–15 years.
- Similar patents tend to focus on extended-release and combination therapies, with a trend toward process and formulation claims.
- Expanding patent protection beyond Cyprus should involve filing in regional and international patent offices.
FAQs
1. Does CY1121643 protect the active compound itself?
No, the patent primarily covers formulations, processes, and specific uses involving the API, not the compound alone.
2. How does the patent landscape impact generic development?
If key patents on the API or formulation expire, generic manufacturers can enter after patent expiry, assuming no additional patent barriers.
3. What is the typical patent term for drugs in Cyprus?
A standard patent term is 20 years from filing, with potential extensions up to 5 years for patent term extensions or SPCs.
4. Should the patent be challenged for invalidity?
No, based on available prior art. However, validity assessments should be conducted before launching generic products.
5. How can patent infringement be avoided?
Design around the claims by developing alternative formulations, manufacturing processes, or dosage forms that differ significantly from the patent claims.
References:
[1] European Patent Office. (2022). Patent landscape reports. EPO.org.
[2] World Intellectual Property Organization. (2021). Patent scope worldwide. WIPO.int.
[3] Cyprus Patent Office. (2023). Patent law and regulations. CyprusPPO.gov.cy.
